Diabetic Medicine

IGT and IFG. Time for revision?
pp. 707-707(1)
Author: Borch-Johnsen, K.

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention
pp. 708-723(16)
Authors: Unwin, N.; Shaw, J.; Zimmet, P.; Alberti, K. G. M. M.

Insulin: in search of a syndrome
pp. 724-729(6)
Authors: Ferrannini, E.; Balkau, B.

Antibodies to GAD in Japanese patients classified as Type 2 diabetes at diagnosis. High titre of GAD Ab is a predictive marker for early insulin treatment—report of west Japan (Kyushu, Yamaguchi, Osaka) study for GAD Ab(+) diabetes
pp. 730-734(5)
Authors: Takino, H.; Yamasaki, H.; Abiru, N.; Sera, Y.; Abe, T.; Kawasaki, E.; Yamaguchi, Y.; Eguchi, K.; Kanazawa, Y.; Nagataki, S.

Surrogate estimates of insulin sensitivity in Chinese diabetic patients and their offspring
pp. 735-740(6)
Authors: Kuo, C. S.; Hwu, C. M.; Kwok, C. F.; Hsiao, L. C.; Weih, M. J.; Lee, S. H.; Lee, Y. S.; Ho, L. T.

Evaluation of a district-wide screening programme for diabetic retinopathy utilizing trained optometrists using slit-lamp and Volk lenses
pp. 741-745(5)
Authors: Hulme, S. A.; Tin-U, A.; Hardy, K. J.; Joyce, P. W.

Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years
pp. 746-751(6)
Authors: Linkeschova, R.; Raoul, M.; Bott, U.; Berger, M.; Spraul, M.

Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes
pp. 752-757(6)
Authors: Fava, D.; Cassone-Faldetta, M.; Laurenti, O.; De Luca, O.; Ghiselli, A.; De Mattia, G.

Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics
pp. 758-761(4)
Authors: Owen, K. R.; Shepherd, M.; Stride, A.; Ellard, S.; Hattersley, A. T.

The evaluation of screening policies for diabetic retinopathy using simulation
pp. 762-770(9)
Authors: Davies, R.; Roderick, P.; Canning, C.; Brailsford, S.

Longitudinal assessment of the development of diabetic polyneuropathy and associated risk factors
pp. 771-776(6)
Authors: van de Poll-Franse, L. V.; Valk, G. D.; Renders, C. M.; Heine, R. J.; van Eijk, J. T. M.

Diabetic ketosis activates lymphomonocyte-inducible nitric oxide synthase
pp. 777-783(7)
Authors: Iori, E.; Calò, L.; Valbusa, D.; Ceolotto, G.; Milani, M.; Pengo, V.; de Kreutzenberg, S. V.; Tiengo, A.; Avogaro, A.

Age of onset possibly associated with the degree of heteroplasmy in two male siblings with diabetes mellitus having an A to G transition at 3243 of mitochondrial DNA
pp. 784-786(3)
Authors: Kato, Y.; Miura, Y.; Inagaki, A.; Itatsu, T.; Oiso, Y.

Ambulatory blood pressure monitoring: is it necessary for the routine assessment of hypertension in people with diabetes?
pp. 787-789(3)
Authors: Strachan, M. W. J.; Gough, K.; McKnight, J. A.; Padfield, P. L.

Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1
pp. 790-792(3)
Authors: Ahrén, B.; Adner, N.; Svartberg, J.; Petrella, E.; Holst, J. J.; Gutniak, M. K.

Type 2 diabetes with onset in the elderly is not a benign disease
pp. 792-794(3)
Authors: Bo, S.; Cavallo-Perin, P.; Gentile, L.; Repetti, E.; Pagano, G.

A case of congenital generalized lipodystrophy with lipoatrophic diabetes developing anti-insulin antibodies
pp. 794-795(2)
Authors: Usui, H.; Shikata, K.; Wada, J.; Sugimoto, T.; Yamana, J.; Oishi, T.; Matsuda, M.; Yoneda, M.; Koshima, I.; Makino, H.

The Houssay phenomenon, another clue to Sheehan's syndrome in a diabetic
pp. 795-795(1)
Authors: Hadithi, M.; Toorians, A.; Heine, R.

The [C282Y/wt] heterozygous HFE genotype is associated with lower blood pressure and HDL-cholesterol in Type 2 diabetes
pp. 796-796(1)
Authors: Hermans, M. P.; Van Lerberghe, S.; Buysschaert, M.

Errata
pp. 797-797(1)

Diabetic Medicine diary
pp. 798-798(1)